Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Cupping therapy offers relief from chronic pain

27 Feb 2020

Patients with chronic pain may benefit from cupping therapy, which is safe and attenuates pain intensity, according to the results of a meta-analysis.

Researchers searched multiple online databases for randomized controlled trials evaluating the effects of cupping on pain intensity and disability in patients with chronic pain. Risk of bias was estimated using the Cochrane risk-of-bias tool.

The meta-analysis included 18 trials (n=1,172), most of which were limited by clinical heterogeneity and risk of bias.

Pooled data revealed that cupping therapy exerted large short-term effects on pain intensity compared with no treatment (standardized mean difference [SMD], –1.03, 95 percent confidence interval [CI], –1.41 to –0.65), although the effects did not differ relative to that conferred by sham cupping (SDM, –0.27, 95 percent CI, –0.58 to 0.05) or other active treatment (SMD, –0.24, 95 percent CI, –0.57 to 0.09).

For disability, cupping had medium-sized short-term effects compared with no treatment (SMD, –0.66, 95 percent CI, –0.99 to –0.34) and with other active treatments (SMD, –0.52, 95 percent CI, –1.03 to –0.0028). The effects were similar relative to that of sham cupping (SMD, –0.26, 95 percent CI, –0.57 to 0.05).

Adverse events occurred with greater frequency among patients treated with cupping vs no treatment. The incidence rates did not significantly differ in comparison with sham cupping or other active treatment.

The findings highlight cupping as a potential treatment option for chronic pain, the researchers said. High quality trials are hence warranted, as current evidence is limited by the clinical heterogeneity and risk of bias.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.